Head/Neck Cancer News

The number of cancer surgeries, chemotherapy treatments and radiation treatments declined dramatically during the first months of the COVID-19 pandemic, study findings published in JAMA Oncology showed.

A virtual town hall meeting featuring a panel of regulatory, pharmacy and procurement experts addressed the ongoing shortage of oncology drugs.

More than 20% of patients undergoing surgery for head and neck cancer are malnourished, according to data published in JAMA Otolaryngology Head & Neck Surgery.

A yoga-based intervention provided beneficial supportive care among a cohort of patients undergoing radiotherapy for head and neck cancer and their caregivers, according to study results.

A virtual mind-body fitness program reduced unplanned hospitalizations, number of hospitalization days and urgent care visits among patients undergoing active cancer treatment, study results showed.

The FDA approved toripalimab-tpzi for two indications as treatment for nasopharyngeal carcinoma, making it the first approved therapy for this malignancy.

Individuals with advanced squamous cell carcinoma who refused adjuvant therapy had worse oncologic outcomes, according to data published in JAMA Otolaryngology Head & Neck Surgery.

The FDA granted accelerated approval to entrectinib for infants aged 1 month and older who have solid tumors that harbor neurotrophic tyrosine receptor kinase, or NTRK, gene fusion for whom there are no effective treatments.

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

Greater travel time appeared associated with reduced participation in genotype-matched clinical trials among patients with cancer who underwent comprehensive genomic profiling, according to results of a study conducted in Japan.